Abstract
Observational and experimental studies suggest that BM-derived stem and progenitor cells may have the capacity to repair damaged cardiovascular tissue and initiate blood vessel growth in regions of ischemia. Despite controversies regarding transdifferentiation potential of adult stem cells, clinical trials are underway testing the hypothesis that BM cell-based approaches to a broad spectrum of cardiovascular diseases and disease presentations will be safe and effective strategies for patient management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
